BRACAnalysis CDx - Myriad

BRACAnalysis CDx - Myriad

BRACAnalysis CDx™ (FDA approved BRCA1/2 test) is the companion diagnostic test intended to be used as an aid in treatment decision making for Lynparza™ (olaparib).1


BRCA1 and BRCA2 are known to cause Hereditary Breast and Ovarian Cancer (HBOC) Syndrome. For over 20 years, Myriad has been dedicated to understanding mutations in these genes as well as reducing the overall variant of uncertain significance rate to ensure that all patients receive answers. Increasing knowledge over the last several years about these genes has changed medical management and now mutations in BRCA1 and BRCA2 genes are one of the indications for treatment with Lynparza2.


Approximately 15% of epithelial ovarian cancer patients are BRCA positive3 71% of BRCA positive ovarian cancer patients are diagnosed over the age of 504 44% of BRCA positive ovarian cancer patients have no family history of cancer3


1  BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib). This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.
2 Lynparza label
3 Alsop, K. et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol., 30, 2654–2663.
4 Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2, and the mismatch repair genes to ovarian cancer in the population. Hum Mol Gen. 2014; (April 30):1-7


Medical specialty
Required sample
Turn around time
2-3 weeks
Sanger Sequencing